Oncothyreon Inc.

110-110th Avenue NE, Suite 685
Bellevue, WA 98004

Phone: (425) 450-0370
Fax: (425) 450-0371

Web Site: http://www.oncothyreon.com/

A. Company Profile

Oncothyreon (NASDAQ:ONTY) is a biotechnology company applying its leading technology in synthetic vaccines and small molecules for the development of cancer therapeutics.

B. Products

Product Pipelines

1. PX-12

PX-12 is an irreversible inhibitor of thioredoxin (Trx-1), a protein that regulates many factors including hypoxia inducible factor (HIF)-1 alpha, vascular endothelial growth factor (VEGF) and activator protein 1 (AP-1). These factors play a critical role in cancer cell growth, survival and resistance to chemotherapy. Increased thioredoxin levels in cancer cells have been linked to the aggressive proliferation of solid tumors, including colon, lung, and gastric cancers.

2. PX-478

PX-478 is a potent inhibitor of HIF-1 alpha, a protein target whose levels are elevated in a wide range of tumors. The protein is a key factor in the response of a cancer cell to hypoxia (lack of oxygen), including the angiogenic cascade that allows tumors to establish new blood vessels essential to their survival and growth. Inhibition of angiogenesis is a validated approach to treating cancer.

3. Stimivax

Stimuvax® is a synthetic 25-amino acid sequence of the cancer-associated marker MUC-1 encapsulated in a specially designed liposomal delivery system. Liposomes, which are fat droplets smaller than red blood cells, are believed to enhance immune recognition of cancer cells. This investigational vaccine offers an innovative approach to treating cancer and potentially prolonging life. It is designed to induce a T-cell immune response to the cancer.